Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Condition:   Metastatic Castration-resistant Prostate Cancer (mCRPC) Interventions:   Drug: Radium-223 (Xofigo, BAY88-8223);   Drug: Abiraterone;   Drug: Enzalutamide Sponsor:   Bayer Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials